Cargando…

Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope

CD4(+) T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, re...

Descripción completa

Detalles Bibliográficos
Autores principales: MacLachlan, Bruce J., Dolton, Garry, Papakyriakou, Athanasios, Greenshields-Watson, Alexander, Mason, Georgina H., Schauenburg, Andrea, Besneux, Matthieu, Szomolay, Barbara, Elliott, Tim, Sewell, Andrew K., Gallimore, Awen, Rizkallah, Pierre, Cole, David K., Godkin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937582/
https://www.ncbi.nlm.nih.gov/pubmed/31619516
http://dx.doi.org/10.1074/jbc.RA119.009437
_version_ 1783483898957660160
author MacLachlan, Bruce J.
Dolton, Garry
Papakyriakou, Athanasios
Greenshields-Watson, Alexander
Mason, Georgina H.
Schauenburg, Andrea
Besneux, Matthieu
Szomolay, Barbara
Elliott, Tim
Sewell, Andrew K.
Gallimore, Awen
Rizkallah, Pierre
Cole, David K.
Godkin, Andrew
author_facet MacLachlan, Bruce J.
Dolton, Garry
Papakyriakou, Athanasios
Greenshields-Watson, Alexander
Mason, Georgina H.
Schauenburg, Andrea
Besneux, Matthieu
Szomolay, Barbara
Elliott, Tim
Sewell, Andrew K.
Gallimore, Awen
Rizkallah, Pierre
Cole, David K.
Godkin, Andrew
author_sort MacLachlan, Bruce J.
collection PubMed
description CD4(+) T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, recent studies have indicated that these regions can influence T-cell receptor (TCR) affinity and pHLA-II stability. Here, using various biochemical approaches including peptide sensitivity ELISA and ELISpot assays, peptide-binding assays and HLA-II tetramer staining, we focused on CD4(+) T-cell responses against a tumor antigen, 5T4 oncofetal trophoblast glycoprotein (5T4), which have been associated with improved control of colorectal cancer. Despite their weak TCR-binding affinity, we found that anti-5T4 CD4(+) T-cells are polyfunctional and that their PFRs are essential for TCR recognition of the core bound nonamer. The high-resolution (1.95 Å) crystal structure of HLA-DR1 presenting the immunodominant 20-mer peptide 5T4(111–130), combined with molecular dynamic simulations, revealed how PFRs explore the HLA-proximal space to contribute to antigen reactivity. These findings advance our understanding of what constitutes an HLA-II epitope and indicate that PFRs can tune weak affinity TCR–pHLA-II interactions.
format Online
Article
Text
id pubmed-6937582
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-69375822020-01-02 Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope MacLachlan, Bruce J. Dolton, Garry Papakyriakou, Athanasios Greenshields-Watson, Alexander Mason, Georgina H. Schauenburg, Andrea Besneux, Matthieu Szomolay, Barbara Elliott, Tim Sewell, Andrew K. Gallimore, Awen Rizkallah, Pierre Cole, David K. Godkin, Andrew J Biol Chem Immunology CD4(+) T-cells recognize peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II), which through peptide-flanking residues (PFRs) can extend beyond the limits of the HLA binding. The role of the PFRs during antigen recognition is not fully understood; however, recent studies have indicated that these regions can influence T-cell receptor (TCR) affinity and pHLA-II stability. Here, using various biochemical approaches including peptide sensitivity ELISA and ELISpot assays, peptide-binding assays and HLA-II tetramer staining, we focused on CD4(+) T-cell responses against a tumor antigen, 5T4 oncofetal trophoblast glycoprotein (5T4), which have been associated with improved control of colorectal cancer. Despite their weak TCR-binding affinity, we found that anti-5T4 CD4(+) T-cells are polyfunctional and that their PFRs are essential for TCR recognition of the core bound nonamer. The high-resolution (1.95 Å) crystal structure of HLA-DR1 presenting the immunodominant 20-mer peptide 5T4(111–130), combined with molecular dynamic simulations, revealed how PFRs explore the HLA-proximal space to contribute to antigen reactivity. These findings advance our understanding of what constitutes an HLA-II epitope and indicate that PFRs can tune weak affinity TCR–pHLA-II interactions. American Society for Biochemistry and Molecular Biology 2019-12-27 2019-10-16 /pmc/articles/PMC6937582/ /pubmed/31619516 http://dx.doi.org/10.1074/jbc.RA119.009437 Text en © 2019 MacLachlan et al. Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0) .
spellingShingle Immunology
MacLachlan, Bruce J.
Dolton, Garry
Papakyriakou, Athanasios
Greenshields-Watson, Alexander
Mason, Georgina H.
Schauenburg, Andrea
Besneux, Matthieu
Szomolay, Barbara
Elliott, Tim
Sewell, Andrew K.
Gallimore, Awen
Rizkallah, Pierre
Cole, David K.
Godkin, Andrew
Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
title Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
title_full Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
title_fullStr Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
title_full_unstemmed Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
title_short Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
title_sort human leukocyte antigen (hla) class ii peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937582/
https://www.ncbi.nlm.nih.gov/pubmed/31619516
http://dx.doi.org/10.1074/jbc.RA119.009437
work_keys_str_mv AT maclachlanbrucej humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT doltongarry humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT papakyriakouathanasios humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT greenshieldswatsonalexander humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT masongeorginah humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT schauenburgandrea humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT besneuxmatthieu humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT szomolaybarbara humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT elliotttim humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT sewellandrewk humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT gallimoreawen humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT rizkallahpierre humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT coledavidk humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope
AT godkinandrew humanleukocyteantigenhlaclassiipeptideflankingresiduestunetheimmunogenicityofahumantumorderivedepitope